ARTICLE | Company News
Nortran cardiovascular news
January 22, 2001 8:00 AM UTC
NRT said it will focus exclusively on cardiovascular indications after Phase II data for the company's CP1 inhaled small molecule that blocks the initiation of cough that did not show a statistically ...